North China Pharmaceutical Co Ltd (600812) — Cash Flow Quality Index
North China Pharmaceutical Co Ltd (600812) has a Cash Flow Quality Index of 4.86x as of September 2025. Operating cash flow of CN¥170.24 Million exceeds net income of CN¥35.01 Million, indicating high earnings quality where cash backs reported profits. Explore investment intensity of North China Pharmaceutical Co Ltd to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
North China Pharmaceutical Co Ltd Cash Flow Quality Index (1998–2025)
Historical Cash Flow Quality Index for North China Pharmaceutical Co Ltd across 25 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check North China Pharmaceutical Co Ltd tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for North China Pharmaceutical Co Ltd (1998–2025)
Year-by-year earnings quality comparison for North China Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see North China Pharmaceutical Co Ltd (600812) market capitalisation.
| Year | Quality Index | Operating CF (CNY) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 6.43x | CN¥1.18 Billion | CN¥183.06 Million | ▲ +12.4% |
| 2024 | 5.72x | CN¥1.23 Billion | CN¥214.97 Million | ▼ -97.3% |
| 2023 | 209.45x | CN¥1.02 Billion | CN¥4.89 Million | ▲ +605.6% |
| 2021 | 29.68x | CN¥1.05 Billion | CN¥35.38 Million | ▲ +312.3% |
| 2020 | 7.20x | CN¥752.15 Million | CN¥104.48 Million | ▲ +45.3% |
| 2019 | 4.96x | CN¥732.97 Million | CN¥147.90 Million | ▼ -6.7% |
| 2018 | 5.31x | CN¥774.33 Million | CN¥145.82 Million | ▼ -73.3% |
| 2017 | 19.90x | CN¥287.25 Million | CN¥14.44 Million | ▲ +330.0% |
| 2016 | -8.65x | CN¥-446.53 Million | CN¥51.63 Million | ▼ -459.0% |
| 2015 | 2.41x | CN¥122.50 Million | CN¥50.85 Million | ▼ -15.4% |
| 2014 | 2.85x | CN¥90.56 Million | CN¥31.79 Million | ▲ +120.0% |
| 2013 | -14.22x | CN¥-135.03 Million | CN¥9.49 Million | ▼ -212.9% |
| 2012 | -4.55x | CN¥-63.92 Million | CN¥14.06 Million | ▼ -379.5% |
| 2011 | 1.63x | CN¥227.60 Million | CN¥139.96 Million | ▲ +171.2% |
| 2010 | -2.29x | CN¥-598.35 Million | CN¥261.81 Million | ▼ -157.7% |
| 2008 | 3.96x | CN¥1.09 Billion | CN¥273.95 Million | ▼ -55.8% |
| 2007 | 8.96x | CN¥664.37 Million | CN¥74.11 Million | ▼ -14.2% |
| 2006 | 10.45x | CN¥597.12 Million | CN¥57.12 Million | ▲ +145.2% |
| 2004 | 4.26x | CN¥310.39 Million | CN¥72.81 Million | ▲ +104.1% |
| 2003 | 2.09x | CN¥580.32 Million | CN¥277.87 Million | ▼ -48.4% |
| 2002 | 4.05x | CN¥738.50 Million | CN¥182.52 Million | ▲ +116.9% |
| 2001 | 1.87x | CN¥367.28 Million | CN¥196.84 Million | ▲ +89.0% |
| 2000 | 0.99x | CN¥133.49 Million | CN¥135.24 Million | ▲ +131.8% |
| 1999 | -3.10x | CN¥-373.62 Million | CN¥120.50 Million | ▼ -13.8% |
| 1998 | -2.73x | CN¥-326.74 Million | CN¥119.90 Million | — |